ADME Project Leader—Genetic Medicines

Eli Lilly and Company

Boston (MA)

On-site

USD 194,000 - 339,000

Full time

38 hours ago

Be an early applicant

Application generator

Turn this role into an interview — a resume and cover letter built around what this employer wants.

Get past ATS filters

Job summary

Eli Lilly and Company in Boston seeks an ADME/DMPK scientist to lead ADME studies supporting Lilly's genetic medicines portfolio. You will work in a multidisciplinary team with chemists, biologists, and engineers to advance preclinical and clinical programs.

The role requires a PhD and 5+ years in pharma/biotech ADME/Pk-Pd, with hands-on PK/PD modeling and biodistribution experience. You will design experiments, interpret data, collaborate across functions, and contribute to regulatory

Qualifications

PhD in Biochemistry/Biology/Pharmacokinetics/Bioengineering/Pharmacology or related field.
5+ years of experience as a scientist in pharma/biotech with ADME or PK/PD.
Knowledge of DMPK and/or bioanalytical considerations for gene editing and/or gene therapy modalities.
Understanding of regulatory guidance and expectations.

Responsibilities

Lead ADME studies to support preclinical and clinical development of the Lilly genetic medicines portfolio.
Integrate ADME, PK and PK/PD data with discovery chemistry and biology data to guide preclinical drug design, optimization, and delivery strategies.
Design, implement, and interpret hypothesis-driven studies to inform key ADME, PK/PD, and toxicokinetic questions.
Collaborate and innovate with cross-functional and interdisciplinary colleagues.
Lead the preparation of ADME portions of regulatory communications and documents to support clinical development and line extensions and interact with global regulatory authorities.